Resources

At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with the bacteria-killing power of an IV to treat patients with serious urinary tract infections.  A frightening sign of our deteriorating antibiotic arsenal is the three...

Beta Bionics has partnered with Zealand Pharma to study at-home use of its iLet Bionic Pancreas System with dasiglucagon for autonomous bihormonal treatment of people living with type 1 diabetes. “Fully automated diabetes care could significantly improve life...

Digital therapeutics startup NightWare has secured breakthrough designation from the US Food and Drug Administration (FDA) for its smart watch app meant to help patients with nightmare disorder. The NightWare app is designed to measure and treat nightmares in people...

Amgen has offered $167 million to buy Nuevolution. The takeover will give Amgen control of a drug discovery platform that landed Nuevolution deals with leading companies plus a pipeline of early-stage cancer and inflammation programs.

A week after launching with $150 million, ElevateBio is unveiling its first portfolio company: AlloVir, a biotech working on off-the-shelf cell therapies against several common viruses, including flu, respiratory syncytial virus and a type of herpes virus.

Women’s healthcare company Ava Science has reported positive data from a clinical trial of its Fertility Tracker, a wearable device designed to identify five most fertile days of a woman’s cycle in real-time. Study data showed that the device was able to...

Google and Northwestern Medicine in the US have conducted a new study to assess the ability of an artificial intelligence (AI) technology to identify lung cancer. “AI in 3D can be much more sensitive in its ability to detect early lung cancer than the human eye...

The US Food and Drug Administration (FDA) has granted premarket approval (PMA) to Stryker’s Neuroform Atlas Stent System for the treatment of brain aneurysms. “PMA approval of Neuroform Atlas Stent System is a significant milestone in providing world-class...

Novartis, Otsuka, Pfizer and Sanofi have signed onto Verily’s Project Baseline, a program aimed at mapping out a baseline for human health.

Ocular Therapeutix’s drug-eluting insert to treat glaucoma—a small, resorbable hydrogel plug that sits within the tear duct and is designed to replace 90 days’ worth of daily eye drops—fell just short of meeting the primary endpoint of its...

K2 HealthVentures has secured $400 million to support public and private companies in life sciences and healthcare. The East Coast investor will primarily provide debt financing to enable companies to reach milestones with minimal equity dilution.

Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. Innovative startups aren’t just about being cool and nimble, having...

Vertex Pharmaceuticals is paying $70 million upfront to work with Kymera Therapeutics on the discovery of drugs that drive the elimination of disease-causing proteins. The early-stage deal features more than $1 billion in milestones tied to the success of six...

Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development, in many cases due to lack of appropriate technologies to drug well credentialed biological targets. Examples in this category include driver...

The IQVIA Institute released a data-rich report in April 2019 on the state of clinical R&D in the US pharmaceutical industry titled “The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial...

It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s been a momentous decade of ups and downs, many of them chronicled in dozens of posts here on LifeSciVC. At 10 years and still going, we’re proud to...

Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and damaging in the worst. And most CEOs enjoy complaining about their...

Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter.  It’s a 2013 New Yorker article chronicling one woman’s journey through years of multi-symptom autoimmune/autoinflammatory disease with undiagnosed and...

“It takes twenty years to build a reputation, and five minutes to ruin it,” Warren Buffett said, and added “If you think about that, you’ll do things differently.” In biotech, a strong reputation is difficult to build, is even harder to...

Machines can measure, but can they “eyeball” something?

Obsidian Therapeutics has named Paul Wotton as CEO. The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics. Read more.

Check out the April 8 Beyond Clean podcast featuring Peter Nichol on the $50 billion dollar savings opportunity that exists by investing in Sterile Processing departments.  Dr. Nichol’s discusses his research facing sterile processing departments...